TABLE 5

ABBV-615, IL-17A-mAb, and IL-1α/IL-1β DVD-Ig

A comparison of 1) exposure data after dosing for 13 weeks at 200 mg/kg per week i.v. or s.c. in cynomolgus monkey; 2) potency and affinity regarding IL-17A and IL-1β; 3) total incidence of skin abscesses at top doses of 200 mg/kg per week; and 4) total incidence of skin abscesses at all dose levels tested. Unit: C_max is milligrams per milliliter; AUC is AUC_0–168h at milligrams × hour per milliliter; affinity and potency IC₅₀ are picomolar.

Compound	200 mg/kg per Week i.v.		200 mg/kg per Week s.c.		Affinity		Potency (IC₅₀)		Overall Incidence Skin Abscesses at 200 mg/kg i.v. and s.c.	Overall Incidence Skin Abscesses at All Dose Levels Tested
Compound	C_max	AUC	C_max	AUC	IL-17A	IL-1β	IL-17A	IL-1β	Overall Incidence Skin Abscesses at 200 mg/kg i.v. and s.c.	Overall Incidence Skin Abscesses at All Dose Levels Tested
Anti–IL-17A mAb^{^a}	9.44	792	4.39	569	0.8	—	9	—	0/16	0/32
Anti–IL-1α/IL-1β DVD-Ig^{^b}	10.9	723	2.90	369	—	28	—	26	0/20	0/40
ABBV-615	11.9	1160	4.95	720	3	12	58	3	5/24	9/40

↵^a Study design of 13-week study: control (i.v./s.c.), 20, 60, and 200 (all i.v.) and 200 s.c.; four animals/group/sex (= a total of 32 animals dosed with anti–IL-17A mAb).
↵^b Study design of 13-week study: control (i.v./s.c.), 50, 100, and 200 (all i.v.) and 200 s.c.; six animals/group/sex in control, 50 and 200 i.v., four animals at 100 mg i.v. and 200 s.c. (= a total of 40 animals dosed with the DVD-Ig).